Founders

Recent Posts

• Agomab Reports Positive Phase 1 Results with AGMB-129, a GI-restricted ALK5 Inhibitor for Fibrostenosing Crohn’s Disease
• Agomab Therapeutics Selected as One of Fierce Biotech’s “Fierce 15” Companies of 2022
• Agomab Raises Additional $40.5 Million Through Series B Extension Bringing Total Amount to $114 Million
• Agomab to Present at 40th Annual J.P. Morgan Healthcare Conference and Announces Additional Upcoming Conference Participations in Q1
• Agomab Expands Team with Reginald Brys as Head of Research and Maria Nichol as Head of IP